96 results
424B3
GRI
GRI Bio Inc
28 Mar 24
Prospectus supplement
4:45pm
all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign … only force the exercise of Series T Warrants subject to the satisfaction of certain equity conditions. The Series T Warrants are not presently subject
424B3
GRI
GRI Bio Inc
28 Mar 24
Prospectus supplement
4:42pm
all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign … only force the exercise of Series T Warrants subject to the satisfaction of certain equity conditions. The Series T Warrants are not presently subject
424B3
GRI
GRI Bio Inc
2 Feb 24
Prospectus supplement
4:25pm
to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction … otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares that the Holder anticipated receiving
8-K
EX-99.1
cx37fq
2 Feb 24
GRI Bio Announces Pricing of $5.5 Million Public Offering
4:23pm
8-K
EX-10.1
zoj7xoqxdxky
2 Feb 24
GRI Bio Announces Pricing of $5.5 Million Public Offering
4:23pm
8-K
EX-4.3
rnjk h0pk2py
2 Feb 24
GRI Bio Announces Pricing of $5.5 Million Public Offering
4:23pm
8-K
EX-4.2
f78ij21d jy90
2 Feb 24
GRI Bio Announces Pricing of $5.5 Million Public Offering
4:23pm
8-K
EX-4.1
m5t9pbmn74q1djs9nuwu
2 Feb 24
GRI Bio Announces Pricing of $5.5 Million Public Offering
4:23pm
424B4
hwmbigr
2 Feb 24
Prospectus supplement with pricing info
4:21pm
424B3
dx5 92plzyxat5uid
15 Dec 23
Prospectus supplement
5:02pm